secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001438533-26-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Q1 net product sales up 64% to $124.5M; FILSPARI approved for FSGS
--------------------------------------------------------------------------

- FILSPARI net sales $105.2M (+88% YoY); 993 new PSFs in IgAN during Q1.
- FDA approved FILSPARI for FSGS on April 13; first patients treated within a week.
- Net loss $37.1M ($0.40/sh) vs $41.2M ($0.47/sh); non-GAAP net income $4.1M ($0.05/sh).
- Phase 3 HARMONY of pegtibatinase restarted; first new patient dosed; topline data due 2H 2027.
- Cash & equivalents $264.7M as of March 31; $25M milestone from Mirum received in April.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/0001438533-26-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/tvtx-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001438533-26-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer